Related Experiment Video
Updated: Sep 19, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Therapeutic effect of galactosyltransferase- and sialyltransferase-encoding mRNA in rheumatoid arthritis
Xinyi Peng1, Yingyu Li2, Xiu Sun3
1Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China; The Key Laboratory of Inflammatory and Immunology Diseases, Shenzhen 518036, China; Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Glycoengineering of IgG, particularly Fc glycosylation, holds significant promise for treating autoimmune diseases by modulating antibody effector functions. However, methods that precisely control IgG glycosylation profiles in vivo are still lacking. In this study, by delivering mRNAs encoding the glycosyltransferases B4GALT1 and ST6GAL1 intravenously, we successfully expressed functional enzymes and demonstrated therapeutic benefits in rheumatoid arthritis animal models in a platelet-dependent manner. We further verified that intra-articular administration effectively ameliorated collagen-induced arthritis in rats. Our findings demonstrate that IgG galactosylation and sialylation, modulated by mRNA drug technology, shift immune responses from pro-inflammatory to anti-inflammatory states, similar to the mechanisms of intravenous immunoglobulin (IVIG) therapies. This study establishes glycosyltransferase-encoding mRNA-LNP technology as a versatile platform for modulating in vivo IgG glycosylation and treating associated diseases.
Glycoengineering of IgG, particularly Fc glycosylation, holds significant promise for treating autoimmune diseases by modulating antibody effector functions. However, methods that precisely control IgG glycosylation profiles in vivo are still lacking. In this study, by delivering mRNAs encoding the glycosyltransferases B4GALT1 and ST6GAL1 intravenously, we successfully expressed functional enzymes and demonstrated therapeutic benefits in rheumatoid arthritis animal models in a platelet-dependent manner. We further verified that intra-articular administration effectively ameliorated collagen-induced arthritis in rats. Our findings demonstrate that IgG galactosylation and sialylation, modulated by mRNA drug technology, shift immune responses from pro-inflammatory to anti-inflammatory states, similar to the mechanisms of intravenous immunoglobulin (IVIG) therapies. This study establishes glycosyltransferase-encoding mRNA-LNP technology as a versatile platform for modulating in vivo IgG glycosylation and treating associated diseases.
More Related Videos
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

